Related Experiment Video
Updated: Aug 11, 2025
05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
263
GDF15 analogs as obesity therapeutics
Samuel N Breit1, David A Brown2, Vicky Wang Wei Tsai1
1St. Vincent's Centre for Applied Medical Research, St. Vincent's Hospital, Sydney and University of New South Wales, Sydney, NSW 2010, Australia.
Cell Metabolism
|February 8, 2023
Summary
Growth Differentiation Factor 15 (GDF15) analogs show therapeutic potential for obesity. A new clinical trial in obese humans investigates the efficacy of a GDF15 analog drug.
Area of Science:
- Metabolic disease research
- Clinical pharmacology
- Obesity therapeutics
Background:
- Growing interest in Growth Differentiation Factor 15 (GDF15) analogs for obesity treatment.
- GDF15 is a cytokine implicated in metabolic regulation and appetite control.
Purpose of the Study:
- To report the first clinical trial of a GDF15 analog in obese humans.
- To evaluate the safety and efficacy of a novel GDF15 analog drug.
Main Methods:
- Phase I/II clinical trial design.
- Recruitment of obese human participants.
- Administration and monitoring of the GDF15 analog.
Main Results:
- The study presents the initial findings from the first clinical trial of a GDF15 analog in obese individuals.
- Results pertaining to drug safety, tolerability, and preliminary efficacy signals are detailed.
Conclusions:
- The first clinical trial of a GDF15 analog in obese humans provides foundational data.
- This study paves the way for further investigation into GDF15 analogs as a potential obesity therapy.
Related Concept Videos
01:24Obesity
567
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
567
01:24Glucagon-like Receptor Agonists
382
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
382
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
253
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
253
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
232
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
232
01:23Dipeptidyl Peptidase 4 Inhibitors
225
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
225
01:15G Protein-coupled Receptors
12.5K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
12.5K